J. Mckendrick

V. Ganju, D. Ball, M. MacManus, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses.

P. Bird, P. Hosking, C. Hirst, 2001, Cellular immunology.

First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.

A. Ravaud, B. Melichar, A. Santoro, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose

P. Gibbs, H. Wong, J. Shapiro, 2013 .

Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature

I. Davis, P. Parente, J. Mckendrick, 2018, Supportive Care in Cancer.

Erratum

J. Sweetenham, J. Whitehouse, J. Mckendrick, 1988, Dementia and Geriatric Cognitive Disorders.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

M. S. Lewis, M. Sydes, D. Wright, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

1LB 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage-III colon cancer

W. Scheithauer, C. Twelves, J. Cassidy, 2007 .

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

J. O’Shaughnessy, C. Twelves, A. Bexon, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Financial incentives in cancer care and impact on prescribing practice.

P. Gibbs, H. Wong, J. Shapiro, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of care of elderly patients with metastatic colorectal cancer.

P. Gibbs, H. Wong, J. Shapiro, 2013 .

Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status

P. Gibbs, L. Lipton, J. Tie, 2013 .

Pulmonary Embolism as an Initial Presentation of Adrenocortical Carcinoma

P. Parente, J. Mckendrick, S. Aung, 2014, World journal of oncology.

Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial.

W. Scheithauer, C. Twelves, J. Cassidy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy

E. Copson, K. Tung, J. Mckendrick, 2004, BJU international.

High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.

J. Sweetenham, J. Whitehouse, J. Mckendrick, 1990, British Journal of Cancer.

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

M. Millward, D. Rischin, M. Boyer, 2000, British Journal of Cancer.

The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.

P. Perlmutter, A. Dear, J. Mckendrick, 2011, International journal of oncology.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study Ann Oncol 2002; 13: 1264–1274

M. S. Lewis, M. Sydes, D. Wright, 2002 .

SAENTA-fluoresceins: New Flow Cytometry Reagents for Assessing Transport of Nucleoside Drugs in Acute Leukemia

J. Wiley, W. Sawyer, P. Dennington, 1992 .

Rituximab in Lymphoma with Life Threatening Haemolysis

J. Mckendrick, Shirley Wong, 2002, Leukemia & lymphoma.

Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma: Treatment effect according to baseline prognostic factors

R. Marcus, A. Belch, P. Solal-Céligny, 2005 .

1089 Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study)

J. Zaluski, J. Douillard, C. Twelves, 2003 .

Nonseminomatous germ cell tumor with very high serum human chorionic gonadotropin

G. Mead, J. Mckendrick, J. Theaker, 1991, Cancer.

Multiple relapses of mature teratoma, germinal and non-germ cell cancer in a patient treated with chemotherapy for testicular non-seminomatous germ cell cancer.

G. Mead, J. Mckendrick, D. Cowlishaw, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

S. Lade, J. Seymour, C. Stern, 2006, British Journal of Cancer.

Brain as sanctuary site of relapse in germ cell cancer patients previously treated with chemotherapy.

S. Crabb, G. Mead, J. Mckendrick, 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma.

G. Mead, J. Sweetenham, J. Whitehouse, 1993, European journal of cancer.

Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

Max Wolf, Joseph McKendrick, George Morstyn, 1994, Annals of Internal Medicine.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

E. Van Cutsem, J. Tabernero, P. Ruff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era

A. Schwarer, E. Hawkes, A. Grigg, 2016, Annals of Hematology.

ChlVPP chemotherapy in advanced Hodgkin's disease.

G. Mead, J. Sweetenham, R. Ryall, 1989, European journal of cancer & clinical oncology.

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

L. Mileshkin, J. Biagi, J. Zeldis, 2003, Blood.

Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter.

J. Szer, J. Cebon, W. Sheridan, 1994, Leukemia.

Cytokine priming of acute myeloid leukemia may produce a pulmonary syndrome when associated with a rapid increase in peripheral blood myeloblasts.

J. Szer, J. Cebon, W. Sheridan, 1993, Blood.

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.

J. Zalcberg, M. Green, R. Fox, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I and Pharmacokinetic Study of Subcutaneously-Administered Recombinant Human Interleukin-4 (rhuIL-4) in Patients with Advanced Cancer

I. Davis, A. Boyd, Michael D. Green, 2000, Growth factors.

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

R. Herrmann, D. Joske, J. Bashford, 2005, Bone Marrow Transplantation.

Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment.

D. Wright, G. Mead, J. Sweetenham, 1989, British Journal of Cancer.

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Charmaine D. Smith, E. Hawkes, M. Burgess, 2023, Leukemia.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

E. Van Cutsem, J. Tabernero, P. Ruff, 2014, European journal of cancer.

Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

E. Van Cutsem, J. Tabernero, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

S. Reingold, W. Scheithauer, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic urachal cancer responding to FOLFOX chemotherapy.

B. Tran, J. Mckendrick, 2010, The Canadian journal of urology.

Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.

P. Gibbs, J. Desai, J. Tie, 2016, Clinical colorectal cancer.

A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC

B. Solomon, L. Mileshkin, D. Ball, 2005, British Journal of Cancer.

Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.

J. Cebon, M. Green, W. Sheridan, 1998, American journal of clinical oncology.

A comparison of quality of life in patients with T3 rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group Trial (TROG 01.04)

R. Fisher, B. Burmeister, M. Solomon, 2008 .

The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression.

M. Voso, A. Dear, J. Duong, 2009, International journal of oncology.

Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801)

D. Goldstein, D. Joseph, R. Fisher, 2005, Diseases of the colon and rectum.

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

J. Zalcberg, M. Jefford, R. Hicks, 2014, British Journal of Cancer.

Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).

K. Kinzler, B. Vogelstein, P. Gibbs, 2018 .

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

A. Scott, L. Churilov, T. Witkowski, 2019, Blood.

Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment.

P. Ruff, R. Lakomy, E. Cutsem, 2013 .

Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study

P. Rougier, W. Schmiegel, C. Weitzel, 2001 .

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer

D. Goldstein, J. Zhi, E. Chen, 2011, Cancer Chemotherapy and Pharmacology.

Capecitabine plus docetaxel combination therapy

J. Hornberger, D. Miles, J. O’Shaughnessy, 2005, Cancer.

Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma

P. Gibbs, J. Desai, H. Wong, 2017, Clinical colorectal cancer.

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

R. Schilsky, E. Van Cutsem, J. Marshall, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia

P. Gibbs, J. Desai, J. Tie, 2015, Asia-Pacific journal of clinical oncology.

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

A. Scott, Charmaine D. Smith, L. Churilov, 2020 .

W. Scheithauer, C. Twelves, J. Cassidy, 2012 .

D. Goldstein, J. Zalcberg, D. Joseph, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).

J. Tabernero, J. Bridgewater, B. Markman, 2012 .

Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer

J. Douillard, C. Twelves, J. Cassidy, 2005 .